心血管疾病(CVDs)的特征是心脏异常,血管,和血液流动。CVD包括一系列不同的健康问题。有几种类型的心血管疾病,比如中风,内皮功能障碍,血栓形成,动脉粥样硬化,斑块不稳定和心力衰竭。鉴定一种用于心脏病的新药需要更长的时间,其安全性有效性测试需要更长的研究和批准时间。本章探讨药物再利用,纳米疗法,以及基于植物的治疗方法,用于管理现有药物的CVD,从而节省了测试新药的时间和安全性问题。现有的药物如他汀类药物,ACE抑制剂,华法林,β受体阻滞剂,已发现阿司匹林和二甲双胍可用于治疗心脏病。为了更好的药物输送,纳米疗法通过靶向白细胞介素(IL)为心脏研究开辟了新的途径,TNF和其他蛋白质通过蛋白质组相互作用分析。纳米颗粒能够精确递送到动脉粥样硬化斑块,炎症区域,和受损的心脏组织。纳米治疗剂的进展,如药物洗脱支架和载药纳米颗粒正在改变心血管疾病的管理。植物性治疗,含有植物来源的植物化学物质,有潜在的心血管益处。这些植物化学物质可以减轻与CVD相关的风险因素。这些策略的整合为个性化开辟了新的途径,有效,和微创心血管护理。总之,传统药物,植物化学物质和纳米颗粒可以通过识别它们的信号通路来彻底改变未来的心脏保健,机制和相互作用组分析。
Cardiovascular diseases (CVDs) are characterized by abnormalities in the heart, blood vessels, and blood flow. CVDs comprise a diverse set of health issues. There are several types of CVDs like stroke, endothelial dysfunction, thrombosis, atherosclerosis, plaque instability and heart failure. Identification of a new drug for heart disease takes longer duration and its safety efficacy test takes even longer duration of research and approval. This chapter explores drug repurposing, nano-therapy, and plant-based treatments for managing CVDs from existing drugs which saves time and safety issues with testing new drugs. Existing drugs like statins, ACE inhibitor, warfarin, beta blockers, aspirin and metformin have been found to be useful in treating cardiac disease. For better drug delivery, nano therapy is opening new avenues for cardiac research by targeting interleukin (IL), TNF and other proteins by proteome interactome analysis. Nanoparticles enable precise delivery to atherosclerotic plaques, inflammation areas, and damaged cardiac tissues. Advancements in nano therapeutic agents, such as drug-eluting stents and drug-loaded nanoparticles are transforming CVDs management. Plant-based treatments, containing phytochemicals from Botanical sources, have potential cardiovascular benefits. These phytochemicals can mitigate risk factors associated with CVDs. The integration of these strategies opens new avenues for personalized, effective, and minimally invasive cardiovascular care. Altogether, traditional drugs, phytochemicals along with nanoparticles can revolutionize the future cardiac health care by identifying their signaling pathway, mechanism and interactome analysis.